General Hospital). Enrollment was performed in a consecutively randomized fashion after obtaining written informed consent from the patients or their legal representatives. All methods were carried out in accordance with approved guidelines.
Dysfunction (MODS) scores were calculated and the inotropic equivalent [dopamine + dobutamine + (epinephrine + norepinephrine + isoproterenol) x 100 + milrinone x15 (mcg/kg/min)] determined (4) .
Indication for dialysis
The pre-determined indications for RRT were: (1) presence of azotemia [blood urea nitrogen (BUN) > 80 mg/dl and serum creatinine (sCr) > 2 mg/dl) with uremic symptoms (encephalopathy, pericarditis or pleurisy); (2) oliguria (urine output < 400 mL/24h) or anuria refractory to diuretics; (3) fluid overload refractory to diuretics with a central venous pressure (CVP) > 12 mmHg or pulmonary edema with a PaO2/FiO2 < 300 mmHg; (4) hyperkalemia (serum potassium >5.5 mmol/l) refractory to medical treatment, and/or (5) metabolic acidosis (aterial pH < 7.
).(5-7)

Dialysis methods
Patients who needed the inotropic equivalent (IE) of more than 15 mcg/kg/min to maintain systolic blood pressure above 120 mmHg, received continuous venovenous hemofiltration (CVVH). Hemofiltration flow and blood flows were 25mL/kg/h and 200 mL/min, respectively. Replacement fluid was bicarbonate-buffered and predilutionally administered at a dynamically adjusted rate to achieve the desired fluid therapy goals. In patients who required an IE of 5-15 mcg/kg/min, sustained low-efficiency daily dialysis (SLEDD) or diafiltration (SLEDD-f) was used with a blood flow of 200mL/min, a dialysate flow of 300mL/min, and a hemofiltration flow of 25mL/kg/h. Duration of treatment was around 6-12 h depending on the amount of ultrafiltration. Intermittent hemodialysis was performed for four h (except for the first and second session) using low-flux polysulphone hemofilter (KF-18C, Kawasumi Laboratories, Japan), with a dialysate and blood flow of 500mL/min. (5, (7) (8) (9) . RRT was performed via a double-lumen central venous catheter in all patients.
cFGF-23 and iFGF-23 measurement
The results yielded by the FGF-23 C-terminal kit were denoted as "cFGF-23" in the current study, which was the combination of the C-terminal fragments and intact
FGF-23 (iFGF-23).(10)
Statistical methods
Continuous data were expressed as mean ± standard deviation (SD) and group comparisons were conducted using χ 2 tests for equal proportions, t tests for normally distributed data, and Wilcoxon rank sum tests otherwise. We generated receiver-operating characteristics (ROC) curves and calculated the area under the curve (AUC) to measure the performance of candidate criteria. Multiple comparisons were analyzed using one-way analysis of variance (ANOVA).
All the relevant covariates, including characteristics, comorbidities, laboratory data, at ICU admission, etiology of AKI, indication for dialysis, dialysis modality, SOFA score, and plasma cFGF-23 at dialysis, and some of their interactions, such as interventions listed in table 1, were put on a selected variable list to predict the outcome of interest. To avoid the extremely over-fitted models, we did not put in outcome, GCS, APACHE II, MODS and kidney function markers other than urine cFGF-23. The significance levels for entry (SLE) and stay (SLS) were conservatively set at 0.15. Then, with the aid of substantive knowledge, the best candidate final logistic regression model was identified manually by dropping the covariates with p > 0.05 until all regression coefficients were significantly different from 0.
Survival curves for all-cause mortality or liberation from dialysis were plotted from adjusted Cox models. For long-term dialysis, an individual who survived at index discharge was censored at death or the end of the study period.
Assessing the performance of prediction models, decision curve analysis (DCA)
Clinical usefulness and net benefit of the cFGF-23 were estimated according with decision curve analyses (DCA)(11), in order to identify patients who will have any of the adverse events evaluated. The DCA show the clinical usefulness of each new model based on a continuum of potential thresholds for adverse events (x-axis) and the net benefit of using the model to stratify patients at risk (y-axis) relative to assuming that no patient will have an adverse event. The basic interpretation of DCA is that the strategy with the highest net benefit at a particular threshold probability has the highest clinical value. In this study, the prediction models are represented by dot lines (AKI risk prediction score) and dashed lines (cFGF-23 and AKI risk prediction score). Those models that are the farthest away from the slanted horizontal grey line (i.e., assume none adverse event) and the slanted balck line (i.e., assume all adverse events) and the horizontal black line (i.e., assume none adverse event) demonstrate the higher net clinical benefit.
All analyses were performed with R software, version 3. indicates a line of identity; for points above this line, the predicted risk is higher in the new model (improved reclassification for events), and for points below this line, the predicted risk is lower (improved reclassification for non-event cases).
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